Movement Alert｜Abivax S.A. Rises 5.18% in Regular Trading, Morgan Stanley Raises Target Price to $180

Market Focus07-30

On July 30, Abivax S.A. rose 5.18% in regular trading, trading at $124.4/share, with turnover of $55.49 million. The rally was driven by Morgan Stanley significantly raising its price target on the company from $132 to $180 while maintaining an Overweight rating.

According to Morgan Stanley's research note, obefazimod — Abivax's lead drug candidate for ulcerative colitis — has demonstrated promising clinical results, with key opinion leaders expressing unanimous support for the drug's efficacy profile, particularly on endoscopic measures. The firm noted that sentiment on lingering regulatory and labeling concerns has improved as clinical data has come in, suggesting broad opportunity for commercial uptake.

Additionally, Abivax closed a $920 million ADS offering in early July, generating estimated net proceeds of approximately $874.1 million. The company stated the funds will support operations into Q4 of 2029 and finance the potential U.S. commercialization of obefazimod. The consensus mean price target among analysts polled stands at $162.06, well above the current trading level.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138028006?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138028006","market":"us","top_or_hot":-1,"title":"Movement Alert｜Abivax S.A. Rises 5.18% in Regular Trading, Morgan Stanley Raises Target Price to $180","media":"Market Focus","content":"<p><p>On July 30, Abivax S.A. rose 5.18% in regular trading, trading at $124.4/share, with turnover of $55.49 million. The rally was driven by Morgan Stanley significantly raising its price target on the company from $132 to $180 while maintaining an Overweight rating.</p><p>According to Morgan Stanley's research note, obefazimod — Abivax's lead drug candidate for ulcerative colitis — has demonstrated promising clinical results, with key opinion leaders expressing unanimous support for the drug's efficacy profile, particularly on endoscopic measures. The firm noted that sentiment on lingering regulatory and labeling concerns has improved as clinical data has come in, suggesting broad opportunity for commercial uptake.</p><p>Additionally, Abivax closed a $920 million ADS offering in early July, generating estimated net proceeds of approximately $874.1 million. The company stated the funds will support operations into Q4 of 2029 and finance the potential U.S. commercialization of obefazimod. The consensus mean price target among analysts polled stands at $162.06, well above the current trading level.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Rises 5.18% in Regular Trading, Morgan Stanley Raises Target Price to $180</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Rises 5.18% in Regular Trading, Morgan Stanley Raises Target Price to $180\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, Abivax S.A. rose 5.18% in regular trading, trading at $124.4/share, with turnover of $55.49 million. The rally was driven by Morgan Stanley significantly raising its price target on the company from $132 to $180 while maintaining an Overweight rating.</p><p>According to Morgan Stanley's research note, obefazimod — Abivax's lead drug candidate for ulcerative colitis — has demonstrated promising clinical results, with key opinion leaders expressing unanimous support for the drug's efficacy profile, particularly on endoscopic measures. The firm noted that sentiment on lingering regulatory and labeling concerns has improved as clinical data has come in, suggesting broad opportunity for commercial uptake.</p><p>Additionally, Abivax closed a $920 million ADS offering in early July, generating estimated net proceeds of approximately $874.1 million. The company stated the funds will support operations into Q4 of 2029 and finance the potential U.S. commercialization of obefazimod. The consensus mean price target among analysts polled stands at $162.06, well above the current trading level.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1138028006","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138028006","pubTimestamp":1785423662,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, Abivax S.A. rose 5.18% in regular trading, trading at $124.4/share, with turnover of $55.49 million. The rally was driven by Morgan Stanley significantly raising its price target on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"走势警报|Abivax S.A. 常规交易中上涨 5.18%，摩根士丹利将目标价上调至 180 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"On July 30, Abivax S.A. rose 5.18% in regular trading, trading at $124.4/share, with turnover of $55.49 million. The rally was driven by Morgan Stanley significantly raising its price target on the company from $132 to $180 while maintaining an Overweight rating.According to Morgan Stanley's research note, obefazimod — Abivax's lead drug candidate for ulcerative colitis — has demonstrated promising clinical results, with key opinion leaders expressing unanimous support for the drug's efficacy profile, particularly on endoscopic measures. The firm noted that sentiment on lingering regulatory and labeling concerns has improved as clinical data has come in, suggesting broad opportunity for commercial uptake.Additionally, Abivax closed a $920 million ADS offering in early July, generating estimated net proceeds of approximately $874.1 million. The company stated the funds will support operations into Q4 of 2029 and finance the potential U.S. commercialization of obefazimod. The consensus mean price target among analysts polled stands at $162.06, well above the current trading level.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138028006","isCrawlerRequest":true}